Medicines | Horizonscan geneesmiddelen

Aztreonam / avibactam Ceftazidime / avibactam ^IND Dalbavancine ^IND Faecal microbiota transplant Gepotidacin Minocycline Ridinilazole Sulopenem Tedizolid ^IND Vonoprazan Zoliflodacin

Abnobaviscum 900 Durvalumab ^IND Enfortumab vedotin ^IND Erdafitinib Mitomycine extended release

Nivolumab

Extension of indication to include in combination with cisplatin-based chemotherapy the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma. ^IND OPDIVO in combination with cisplatin-based chemotherapy is indicated for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma. ^IND

Sacituzumab Govitecan ^IND Sasanlimab

Apraglutide Etrasimod Glepaglutide

Guselkumab

Tremfya is geïndiceerd voor de behandeling van volwassen patiënten met matig tot ernstig actieve ziekte van Crohn die onvoldoende hebben gereageerd op, niet meer reageren op of intolerant waren voor conventionele behandeling of een biologische behandeling. ^IND Tremfya is geïndiceerd voor de behandeling van volwassen patiënten met matig tot ernstige colitis ulcerosa die onvoldoende hebben gereageerd op, niet meer reageren op of intolerant waren voor conventionele behandeling of een biologische behandeling. ^IND

Mirikizumab

Omvoh is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment Extension to include treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment ^IND

Obefazimod ^IND Risankizumab ^IND Teduglutide ^BS Upadacitinib ^IND Ustekinumab ^IND

2-hydroxy Oleic Acid Berubicin Dordaviprone Paclitaxel trevatide Vorasidenib

Abemaciclib ^IND Atezolizumab ^IND

Camizestrant

Camizestrant in combination with CDK4/6 inhibitors for add-on treatment of locoregionally recurrent or metastatic ER-positive, HER2-negative, ESR1-positive Breast cancer in adults and elderly. (SERENA-6) Camizestrant in combination with palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease.

Capivasertib

Datopotamab deruxtecan

Datopotamab deruxtecan as monotherapy is indicated for the treatment of adult patients with inoperable or metastatic HR-Positive, HER2-negative Breast Cancer who have been treated with one or two prior lines of systemic chemotherapy. ^IND Datopotamab deruxtecan as monotherapy is indicated for the treatment of adult patients with locally recurrent inoperable or metastatic Triple-Negative Breast Cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. ^IND

Elacestrant

Gedatolisib

Gedatolisib in combination with fulvestrant for second line or later treatment of advanced or metastatic PIK3CA wild-type hormone receptor positive HER2 negative breast cancer in adults and elderly previously treated with CDK4/6 and aromatase inhibitor therapy Gedatolisib in combination with palbociclib and fulvestrant for second line or later treatment of advanced or metastatic PIK3CA mutated Hormone receptor positive HER2 negative breast cancer in adults and elderly previously treated with CDK4/6 and aromatase inhibitor therapy.

Imlunestrant Inavolisib Lasofoxifene Olaparib ^IND Palbociclib ^IND Ribociclib ^IND Sacituzumab govitecan ^IND

Trastuzumab deruxtecan

Enhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received two or more prior anti HER2 based regimens. Enhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2‑low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy ^IND Extension of indication to include treatment of HER2-low/ultra-low hormone receptor positive breast cancer patients whose disease has progressed on endocrine therapy in the metastatic setting. ^IND

Vepdegestrant

Acalabrutinib ^IND Iopofosine I 131 Pirtobrutinib ^IND

Zanubrutinib

Extension of indication to include treatment of adult patients with chronic lymphocytic leukaemia (CLL). ^IND Extension of indication to include treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one-prior anti-CD20-based therapy ^IND

Bosutinib ^IND

Dupilumab ^IND Ensifentrine

Casirivimab / imdevimab ^IND Remdesivir ^IND Sabizabulin Sipavibart Vilobelimab

Secukinumab ^IND

Cadonilimab Durvalumab ^IND Olaparib ^IND Pembrolizumab ^IND Tisotumab vedotin

Fruquintinib Nivolumab ^IND Pembrolizumab / favezelimab Zanzalintinib

Ivacaftor / Tezacaftor / Elexacaftor ^IND Vanzacaftor / tezacaftor / deutivacaftor ^IND

Blarcamesine Donanemab Lecanemab

Agomelatine ^IND Zuranolone

Canagliflozine ^IND Dasiglucagon Deudomperidone Empagliflozine / metformine ^IND Insulin icodec Insulin icodec / semaglutide Regulatoire T-cellen (TREGS) Teplizumab

Ataluren ^G Delandistrogene moxeparvovec Fordadistrogene movaparvovec Givinostat Vamorolone Viltolarsen

Diazepam nasaal Midazolam ^IND

Acoltremon Avacincaptad pegol Bevacizumab-vikg Bimatoprost Botaretigene sparoparvovec Brimonidine tartrate/carbachol Ciclosporine Faricimab ^IND IBI311 Laruparetigene zosaparvovec Mercaptamine ^IND OCU400 Pegcetacoplan ^IND Polihexanide RGX-314 Ranibizumab Tarcocimab tedromer Timrepigene emparvovec Varenicline Veligrotug

Isavuconazole ^IND Olorofim Rezafungin

Belumosudil MaaT013 Ruxolitinib

Darunavir / Cobicistat ^IND Dolutegravir/ abacavir /lamivudine ^IND Lenacapavir ^IND

Rilpivirine

Edurant, in combination with other antiretroviral medicinal products, is indicated for the treatment of human immunodeficiency virus type 1 (HIV 1) infection in adults and paediatric patients weighing at least 25 kg without known mutations associated with resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, and with a viral load ≤ 100,000 HIV 1 RNA copies/ml ^IND Extension of indication to include in combination with cabotegravir injection, the treatment of adolescents (at least 12 years of age and weighing at least 35 kg) for Rekambys ^IND

Semzuvolimab

Buparlisib Cetuximab sarotalocan Leukocyte interleukin Tislelizumab ^IND Xevinapant

Atogepant

Damoctocog alfa pegol ^IND Emicizumab ^IND Etranacogene dezaparvovec Fidanacogene elaparvovec Turoctocog alfa pegol ^IND Valoctocogene roxaparvovec

Brentuximab vedotin ^IND

Epcoritamab ^IND Lacutamab Lisocabtagene maraleucel ^IND Mosunetuzumab ^IND Tafasitamab ^IND Zanubrutinib ^IND

Cefepime / enmetazobactam Cefepime/taniborbactam

Abexinostat Belzutifan Cabozantinib ^IND Nivolumab/hyaluronidase Ph20 ^IND Zanzalintinib

Evinacumab ^IND

Lerodalcibep

Cardiovascular disorder in adults and elderly on a stable diet and oral LDL-C lowering drug therapy with history of CVD, monotherapy for add-on treatment Heterozygous Familial Hypercholesterolemia ^IND

Lomitapide ^IND Pravastatine / fenofibraat ^IND

Atezolizumab ^IND Camrelizumab

Durvalumab

Durvalumab (+/- bevacizumab) in combinatie met TACE in patiënten met locoregionale HCC. ^IND Imfinzi as monotherapy is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC). ^IND

Lenvatinib ^IND Namodenoson Nivolumab ^IND Nofazinlimab Tremelimumab

Arachidyl amido cholanoic acid Elafibranor

Maralixibat

Treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) 2 months of age and older. Extension of indication to include treatment of Progressive Familial Intrahepatic Cholestasis (PFIC) in patients 3 months of age and older ^IND

Obeticholic acid Odevixibat ^IND Resmetirom Seladelpar

Alectinib ^IND

Amivantamab

Amivantamab in combination with carboplatin and pemetrexed for the first‑line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with activating EGFR Exon 20 insertion mutations. ^IND Amivantamab in combination with lazertinib is indicated for the treatment of adult patients with epidermal growth factor receptor (EGFR) mutation (Exon 19 deletions [Exon 19del] or Exon 21 L858R substitution) positive, locally advanced or metastatic non-small cell lung cancer (NSCLC). ^IND In combination with carboplatin and pemetrexed for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with EGFR Exon 19 deletions or Exon 21 L858R substitution mutations after failure of prior therapy including an EGFR tyrosine kinase inhibitor. ^IND

Atezolizumab

Subcutaneous formulation of atezolizumab for treatment of PD-(L)-1 Cancer Immunotherapy in multiple tumor types. ^IND Tecentriq as monotherapy is indicated for the first-line treatment of adult patients with advanced NSCLC who are ineligible for platinum-based therapy. ^IND

Aumolertinib (mesilate) Cobolimab Datopotamab deruxtecan Domvanalimab

Durvalumab

Lokaal gevorderd, niet-resectabel NSCLC (stadium III) ^IND Completely resected NSCLC ^IND Limited stage small cell lung cancer (LS-SCLC) following concurrent platinum-based chemotherapy and radiation therapy in combination with Tremelimumab. ^IND Extension of indication to include IMFINZI in combination with platinum-based chemotherapy as neoadjuvant treatment, followed by IMFINZI as monotherapy after surgery, for the treatment of adults with resectable (tumours ≥ 4 cm and/or node positive) NSCLC and no known EGFR mutations or ALK rearrangements. ^IND

Encorafenib ^IND Furmonertinib Ivonescimab Lazertinib Lenvatinib ^IND Lurbinectedin Ociperlimab

Osimertinib

Extension of indication to include treatment of adult patients with locally advanced, unresectable NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations and whose disease has not progressed during or following platinum based chemoradiation therapy. ^IND Osimertinib in combination with pemetrexed and platinum based chemotherapy for locally advanced (clinical stage IIIB, IIIC) or metastatic Non-Small Cell Lung Cancer (NSCLC) (clinical stage IVA or IVB) or recurrent Non-Small Cell Lung Cancer (NSCLC) not amenable to curative surgery or radiotherapy. ^IND Neoadjuvant Osimertinib as Monotherapy or in Combination With Chemotherapy Versus Standard of Care Chemotherapy Alone for the Treatment of Patients With Epidermal Growth Factor Receptor Mutation Positive, Resectable Non-small Cell Lung Cancer ^IND

Patritumab deruxtecan ^IND Pembrolizumab ^IND Pembrolizumab / vibostolimab Pembrolizumab/hyaluronidase ^IND Retifanlimab ^IND Sacituzumab Govitecan ^IND Serplulimab Sugemalimab Tarlatamab

Tiragolumab

In combination with atezolizumab for first line treatment of locally advanced, unresectable stage III Non-small cell lung cancer in adults and elderly who have no progression during or following concurrent platinum-based chemoradiotherapy. Tiragolumab in combination with Atezolizumab for first line treatment of locally advanced unresectable or metastatic high PD-L1, EGFR-negative, ALK-negative Non-small cell lung cancer in adults and elderly.

Tislelizumab

Tizveni as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer after prior platinum-based therapy. Patients with EGFR mutant or ALK positive NSCLC should also have received targeted therapies before receiving tislelizumab Tizveni in combination with carboplatin and either paclitaxel or nab-paclitaxel is indicated for the first-line treatment of adult patients with squamous non-small cell lung cancer who have locally advanced NSCLC and are not candidates for surgical resection or platinum-based chemoradiation, or metastatic NSCLC Tizveni in combination with pemetrexed and platinum‑containing chemotherapy is indicated for the first-line treatment of adult patients with non-squamous non-small cell lung cancer whose tumours have PD-L1 expression on ≥50% of tumour cells with no EGFR or ALK positive mutations and who have locally advanced NSCLC and are not candidates for surgical resection or platinum-based chemoradiation, or metastatic NSCLC Locally advanced or metastatic (Stage IIIB or IV), NSCLC (squamous or non-squamous) who have disease progression during or after a platinum-containing regimen. ^IND Extension of indication to include first-line treatment of adult patients with extensive-stage Small Cell Lung Cancer (SCLC) for Tevimbra in combination with etoposide and platinum chemotherapy ^IND

Trastuzumab deruxtecan ^IND Tremelimumab

Benralizumab

Patients with severe bilateral nasal polyposis who are still symptomatic despite standard of care therapy, i.e current use of intranasal corticosteroids (INCS) and prior surgery and/or use of systemic corticosteroids. ^IND Extension of indication to include treatment of eosinophilic granulomatosis. ^IND

Brensocatib Efzofitimod ^BS Gefapixant

Nintedanib

Treatment of chronic fibrosing interstitial lung diseases in paediatric patients from 6 to 17 years. ^IND Nintedanib Accord is a medicine used to treat adults with idiopathic pulmonary fibrosis (IPF), a disease of unknown cause in which fibrous tissue forms in the lungs; systemic sclerosis associated interstitial lung disease, a disease in which the immune system (the body’s natural defences) is overactive, causing production of fibrous tissue and progressive scarring of the lungs; other chronic fibrosing interstitial lung diseases which are progressive. ^G

Pamrevlumab Sotatercept Tezepelumab ^IND Zinpentraxin alfa

Avalglucosidase alfa Cipaglucosidase alfa Dasiglucagon ^IND Eliglustat ^IND Elinzanetant Encaleret Fezolinetant

Govorestat

Patients with Classic Galactosaemia aged 2 to 65 years. Sorbitol dehydrogenase deficiency

Leriglitazone Liraglutide ^IND N-Acetyl-L-Leucine Nedosiran Olezarsen Paltusotine Pegunigalsidase alfa Plozasiran RGX-111 RGX-121 Rebisufligene etisparvovec Relacorilant Sepiapterin Somapacitan Somatrogon ^IND Sparsentan Tiomolibdate choline

Belantamab mafodotin

Multiple Myeloma 3L ^IND Second line treatment of r/r multiple myeloma in adults and elderly, in combination with bortezomib and dexamethasone, or pomalidomide and dexamethasone ^IND

Ciltacabtagene autoleucel ^IND

Daratumumab

Extension of indication for Darzalex in combination with bortezomib, lenalidomide and dexamethasone for the treatment of newly diagnosed multiple myeloma, to include also adult patients who are not eligible for stem cell transplant (SCT) ^IND In combination with bortezomib, lenalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant ^IND

Elranatamab Idecabtagene vicleucel ^IND

Isatuximab

Extension of indication to include in combination with bortezomib, lenalidomide, and dexamethasone, for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. ^IND In combination with bortezomib, lenalidomide and dexamethasone (Isa VRd) in patients with newly diagnosed multiple myeloma (NDMM) eligible for transplant. ^IND Isatuximab in combination with pomalidomide and dexamethasone for second line or later treatment of relapsed and/or refractory multiple myeloma in adults and elderly who have received at least one prior line of therapy including lenalidomide and a proteasome inhibitor ^IND

Selinexor ^IND Talquetamab Teclistamab Venetoclax ^IND

Tolebrutinib Ublituximab

ANX-005 Baclofen / naltrexone / sorbitol Bidridistrogene xeboparvovec Dantroleen ^G Doxecitine / doxiribtimine Efgartigimod Inebilizumab ^IND Losmapimod Nipocalimab Omaveloxolone Rozanolixizumab Satralizumab ^IND Sugammadex ^IND Zilucoplan

Avapritinib ^IND Momelotinib Navitoclax Pacritinib Peginterferon alfa-2a ^IND Pelabresib Pemigatinib ^IND Pivekimab Sunirine

Cabozantinib ^IND Lutetium (177Lu) edotreotide Lutetium (177Lu) oxodotreotide ^IND Lutetium (177Lu) zadavotide guraxetan Mirdametinib

Deutetrabenazine (Extended release) Efgartigimod alfa / hyaluronidase-qvfc ^IND Eplontersen Glycopyrronium ^IND Nepla-tem-cel Pridopidine Tiratricol ^G Trofinetide Troriluzole

Vutrisiran

treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy. Extension of indication to include treatment of wild-type or hereditary transthyretin-mediated amyloidosis in adult patients with cardiomyopathy (ATTR-CM) ^IND

Afamitresgene autoleucel Belzutifan Bezuclastinib Catequentinib Catumaxomab

Dostarlimab

Extension of indication to include in combination with carboplatin and paclitaxel for the treatment of adult patients with mismatch repair deficient (dMMR)/ microsatellite instability high (MSI H) primary advanced or recurrent endometrial cancer (EC) and who are candidates for systemic therapy ^IND MMRp EC ^IND

Durvalumab ^IND Efbemalenograstim alfa Entrectinib ^IND Ivosidenib Letetresgene autoleucel Melphalan hydrochloride Nirogacestat Ozekibart

Pembrolizumab

Keytruda, in combination with pemetrexed and platinum chemotherapy, is indicated for the first‑line treatment of adults with unresectable non-epithelioid malignant pleural mesothelioma. ^IND Keytruda, in combination with carboplatin and paclitaxel, is indicated for the first-line treatment of primary advanced or recurrent endometrial carcinoma in adults who are candidates for systemic therapy ^IND

Pimicotinib Repotrectinib

Retifanlimab

Patiënten met inoperabele, lokaal gevorderd of gemetastaseerd plaveiselcarcinoom van het anale kanaal. ZYNYZ is geïndiceerd als monotherapie voor de eerstelijnsbehandeling bij volwassen patiënten met gemetastaseerd of recidiverend lokaal gevorderd merkelcelcarcinoom (MCC) dat niet vatbaar is voor curatieve chirurgie of bestraling.

Selinexor ^IND Sugemalimab ^IND Tebentafusp Tislelizumab ^IND

Toripalimab

Loqtorzi, in combination with cisplatin and gemcitabine, is indicated for the first-line treatment of adult patients with recurrent, not amenable to surgery or radiotherapy, or metastatic nasopharyngeal carcinoma. Loqtorzi, in combination with cisplatin and paclitaxel, is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma.

Varegacestat Vimseltinib Zanidatamab

Allergeenextract huisstofmijt ^IND Arachis hypogaea (pinda) allergenen ^IND Atrasentan Avapritinib ^IND Belimumab ^IND Benralizumab ^IND Budesonide ^IND Donidalorsen

Dupilumab

Dupixent is geïndiceerd voor de behandeling van eosinofiele oesofagitis in volwassenen, adolescenten en kinderen van 1 jaar en ouder, die ongecontroleerd zijn op, intolerant zijn voor, of die geen kandidaat zijn voor conventionele therapie. ^IND Dupixent is indicated for the treatment of moderate to severe chronic spontaneous urticaria in adults and adolescents 12 years and older, who are symptomatic despite treatment with H1 antihistamines and who are intolerant to or inadequately controlled by anti-IgE therapy. ^IND

Epinephrine Iptacopan ^IND Leniolisib Lorecivivint Marnetegragene autotemcel Mycofenolaatmofetil ^IND Obinutuzumab ^IND Pegcetacoplan ^IND Ritlecitinib Sarilumab ^IND Sebetralstat Teprotumumab

Lenzilumab

Acoramidis Aficamten Bempedoic acid / ezetimibe ^IND Etripamil Finerenon ^IND Macitentan ^IND Macitentan / tadalafil Neoatricon (dopamine) Rilonacept ^BS Zalunfiban

Alpelisib Autologous human chondrocytes in vitro expanded Copper histidine Linzagolix ^IND Navepegritide Pegzilarginase Relugolix / estradiol / norethisterone acetaat ^IND

Semaglutide

For weight management in people with obesity or who are overweight and have other related conditions. Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adolescents ages 12 years and above with obesity and body weight above 60 kg. Treatment with Wegovy should be discontinued and re-evaluated if adolescent patients have not reduced their BMI by at least 5% after 12 weeks on the 2.4 mg or maximum tolerated dose. ^IND Extension of indication to include risk reduction of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and BMI ≥27 kg/m2. ^IND Op dit moment heeft oraal semaglutide reeds een indicatie voor diabetes. De aan te vragen indicatie uitbreiding zal slaan op het behandelen van obesitas. ^IND

Setmelanotide ^IND Setrusumab Tirzepatide ^IND

Apadamtase alfa Aprocitentan Benralizumab ^IND Concizumab Crovalimab Danicopan Efanesoctocog alfa ^IND Eltrombopag ^IND Exagamglogene autotemcel Giroctocogene fitelparvovec Iptacopan Luspatercept ^IND Marstacimab Mim 8 Mitapivat ^IND Mozafancogene autotemcel Pegcetacoplan ^IND Pozelimab Rilzabrutinib Rusfertide Vadadustat

Catequentinib Dostarlimab ^IND Mirvetuximab soravtansine Olaparib ^IND

Gemcitabine ^IND Glufosfamide

177Lu-PNT2002 Aglatimagene besadenovec Apalutamide ^IND Atezolizumab ^IND Capivasertib ^IND

Darolutamide

Nubeqa is indicated for the treatment of adult men with metastatic hormone‑sensitive prostate cancer (mHSPC) in combination with docetaxel and androgen deprivation therapy . ^IND Extension of indication to include in combination with androgen deprivation therapy (ADT) the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) ^IND

Lutetium (177lu) vipivotide tetraxetan Niraparib ^IND Niraparib-abirateron fixed dose combinatie ^IND Olaparib ^IND Radium-223 ^IND Relugolix Rucaparib ^IND

Talazoparib

Talzenna is indicated in combination with enzalutamide for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated. ^IND Talzenna in combinatie met enzalutamide is geïndiceerd voor de eerstelijnsbehandeling van patiënten met een gemetastaseerd, hormoonsensitief HRR+ prostaatcarcinoom ^IND

Bimekizumab

Bimzelx is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (NSAIDs), and for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy. ^IND Bimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs). ^IND

Dapansutrile Filgotinib ^IND Golimumab ^BS Inebilizumab ^IND Ixekizumab ^IND Sarilumab ^IND Upadacitinib ^IND

Apitegromab

Brexpiprazol ^IND Brilaroxazine Cycloserine / lurasidon Olanzapine (long-acting injectable) Roluperidon Xanomeline/ trospium

Daromun IO102-IO103 Ipilimumab ^IND Lifileucel Nemvaleukin alfa ^IND Nivolumab/relatlimab/hyaluronidase Ph20 Relatlimab / nivolumab Tucidinostat

Apremilast ^IND Beremagene geperpavec Bimekizumab ^IND Clascoterone Concentrate of proteolytic enzymes enriched in bromelain ^IND Dabocemagene autoficel Delgocitinib Deucravacitinib Guselkumab ^IND Lebrikizumab Nemolizumab Piclidenoson Prademagene zamikeracel Remibrutinib Roflumilast topicaal ^IND

Ruxolitinib (als fosfaat)

Opzelura is indicated for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age. Opzelura is geïndiceerd voor de behandeling van volwassenen met matige atopische dermatitis die eerder zijn behandeld met topische corticosteroïden of topische calcineurineremmers of waarbij deze middelen zijn gecontra-indiceerd. ^IND Prurigo nodularis (PN) ^IND

Spesolimab ^IND

Melatonine ^IND Tasimelteon ^IND Tirzepatide ^IND

Dorocubicel Nomacopan

Bemarituzumab Ripretinib Tislelizumab ^IND Trastuzumab deruxtecan ^IND Zolbetuximab

Selpercatinib ^IND

MDM2-p53 antagonist Selpercatinib ^IND

ARINA-1 Apremilast ^G Atacicept Colistimethate Sodium ^IND Dostarlimab Exoflo Extracellular Vesicles Mirabegron ^IND Olezarsen Pitavastatine Tovorafenib Vibegron

Baloxavir marboxil ^IND Bulevirtide ^IND Clesrovimab ^IND

Letermovir

Extension of indication to include treatment of prophylaxis of CMV disease in CMV-seronegative adults who have received a kidney transplant from a CMV-seropositive donor [D+/R-]. ^IND Extension of Letermovir From Day 100 to Day 200 Post-transplant for the Prevention of Cytomegalovirus Infection in Hematopoietic Stem Cell Transplant. ^IND Letermovir monotherapy for prophylactic treatment of cytomegalovirus infection reactivation in newborns, infants and toddlers, children and adolescents who are at risk of developing CMV infection following an allogeneic haematopoietic stem cell transplantation ^IND

Nirsevimab ^IND Posoleucel

Published on 3 December 2024

ADHD

ALL

ALS

AML / MDS

Aggressive non-Hodgkin’s lymphoma

Acalabrutinib

Glofitamab

Lisocabtagene maraleucel

Tafasitamab

Antithrombotic medications

Asthma

Bacterial infections

Bladder cancer

Nivolumab

Bowel diseases

Guselkumab

Mirikizumab

Brain cancer

Breast cancer

Camizestrant

Datopotamab deruxtecan

Gedatolisib

Trastuzumab deruxtecan

CLL

Zanubrutinib

CML

COPD

COVID-19

Cardiovascular diseases

Cervical cancer

Colon cancer

Cystic fibrosis

Dementia

Depression

Diabetes

Duchenne

Epilepsy

Eye disorders

Fungal infections

Graft versus Host

HIV

Rilpivirine

Head and neck cancer

Headache

Hemostasis promoting medication

Hodgkin's lymphoma

Indolent non-Hodgkin’s lymphoma

Infectious diseases other

Kidney cancer

Lipid-lowering medications

Lerodalcibep

Liver cancer

Durvalumab

Liver diseases

Maralixibat

Lung cancer

Amivantamab

Atezolizumab

Durvalumab

Osimertinib

Tiragolumab

Tislelizumab

Lung diseases other

Benralizumab

Nintedanib

Metabolic diseases

Govorestat

Multiple Myeloma

Belantamab mafodotin

Daratumumab

Isatuximab

Multiple sclerosis

Muscular diseases other

Myeloproliferative disorders

Neuroendocrine cancer

Neurological disorders other

Vutrisiran

Oncology other

Dostarlimab